1334411-79-8

Basic information

• Product Name: 4-broMo-2-(2,6-dichlorophenyl)-1H-iMidazo[4,5-c]pyridine
• Synonyms: 4-broMo-2-(2,6-dichlorophenyl)-1H-iMidazo[4,5-c]pyridine;4-BroMo-2-(2,6-dichlorophenyl)-3H-iMidazo[4,5-c]pyridine;2-[2,6-dichlorophenyl]-4-Bromo-2H-imidazo[4,5-c]pyridine
• CAS NO: 1334411-79-8
• Molecular Formula: C₁₂H₆BrCl₂N₃
• Molecular Weight: 343.00614
• Mol File: 1334411-79-8.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 536.6±60.0 °C(Predicted)
• Appearance: /
• Density: 1.770±0.06 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 8.65±0.40(Predicted)
• CAS DataBase Reference: 4-broMo-2-(2,6-dichlorophenyl)-1H-iMidazo[4,5-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-2-(2,6-dichlorophenyl)-1H-iMidazo[4,5-c]pyridine(1334411-79-8)
• EPA Substance Registry System: 4-broMo-2-(2,6-dichlorophenyl)-1H-iMidazo[4,5-c]pyridine(1334411-79-8)

Safety Data

• Hazardous Substances Data: 1334411-79-8(Hazardous Substances Data)

Usage

General Description

4-bromo-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine is a chemical compound with the molecular formula C11H6BrCl2N3. It is a heterocyclic compound that consists of a pyridine ring fused to an imidazole ring, with bromine and two chlorine substituents on the phenyl ring. 4-bromo-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine has been studied for its potential biological activities, including its effects on the central nervous system and its potential as an antitumor agent. It has also been investigated for its potential use in the development of pharmaceuticals. Additionally, it may have applications in the field of organic synthesis for the preparation of other heterocyclic compounds. Overall, 4-bromo-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine is a compound of interest for its potential biological activities and synthetic uses.

Upstream product

• 39217-08-8 2-chloropyridine-3,4-diamine 
• 50-30-6 2,6-dichlorobenzoic acid 
• 4659-45-4 2,6-Dichlorobenzoyl chloride 
• 83-38-5 2,6-dichlorobenzaldehyde 
• 1334411-81-2 4-chloro-2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridine 
• 1334411-80-1 2-(2,6-dichlorophenyl)-1H-imidazo[4,5-c]pyridin-4-ol 

Downstream Products

• 1334411-89-0 C₁₃H₈BrCl₂N₃ 
• 1334411-91-4 C₁₃H₈BrCl₂N₃ 
• 1334407-17-8 1-(2-(2,6-dichlorophenyl)-3H-imidazo[4,5-c]pyridin-4-yl)-3-methylurea 
• 1334407-07-6 2-(2,6-dichlorophenyl)-N-(pyridin-2-yl)-1H-imidazo[4,5-c]pyridin-4-amine 
• 1334407-09-8 2-(2,6-dichlorophenyl)-N-(1H-pyrazol-4-yl)-3H-imidazo[4,5-c]-pyridin-4-amine 
• 1334407-10-1 N-(6-chloropyrimidin-4-yl)-2-(2,6-dichlorophenyl)-3H-imidazo[4,5-c]pyridin-4-amine 
• 1334407-11-2 2-(2,6-dichlorophenyl)-N-(6-morpholinopyrimidin-4-yl)-3H-imidazo[4,5-c]pyridin-4-amine 
• 1334407-13-4 N-(2-(2,6-dichlorophenyl)-3H-imidazo[4,5-c]pyridin-4-yl)thiazole-5-carboxamide 
• 1334407-15-6 (1S,2S)-N-(2-(2,6-dichlorophenyl)-3H-imidazo[4,5-c]pyridin-4-yl)-2-fluorocyclopropanecarboxamide 
• 1334407-14-5 (1R,2R)-N-(2-(2,6-dichlorophenyl)-3H-imidazo[4,5-c]pyridin-4-yl)-2-fluorocyclopropanecarboxamide 
• 1334408-20-6 C₁₆H₁₂Cl₂N₄O 
• 1334407-18-9 N-(2-(2,6-dichlorophenyl)-1-methyl-1H-imidazo[4,5-c]pyridine-4-yl)cyclopropanecarboxamide 
• 1334407-19-0 N-(2-(2,6-dichlorophenyl)-3-methyl-3H-imidazo[4,5-c]pyridine-4-yl)cyclopropanecarboxamide 

Relevant articles and documents

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model

Herein we report identification of an imidazopyridine class of potent and selective TYK2 inhibitors, exemplified by prototype 6, through constraint of the rotatable amide bond connecting the pyridine and aryl rings of compound 1. Further optimization led to generation of compound 30 that potently inhibits the TYK2 enzyme and the IL-23 pathway in cells, exhibits selectivity against cellular JAK2 activity, and has good pharmacokinetic properties. In mice, compound 30 demonstrated dose-dependent reduction of IL-17 production in a PK/PD model as well as in an imiquimod-induced psoriasis model. In this efficacy model, the IL-17 decrease was accompanied by a reduction of ear thickness indicating the potential of TYK2 inhibition as a therapeutic approach for psoriasis patients.